TipRanks
Nova Leap Health Corp (TSE:NLH)
:NLH
Canadian Market
Want to see TSE:NLH full AI Analyst Report?

Nova Leap Health (NLH) AI Stock Analysis

15 Followers

Top Page

TSE:NLH

Nova Leap Health

(NLH)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - Gpt-5.6Sol)
Rating:68Neutral
Price Target:
C$0.47
▼(-16.25% Downside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by improving (but still inconsistent) financial performance—profitability has returned and leverage is conservative, but margins and cash conversion remain uneven. Technical signals are a meaningful positive with price above key moving averages and positive momentum indicators, partially offset by near-overbought stochastic readings. Valuation is a modest headwind given the P/E level and lack of dividend support in the provided data.
Positive Factors
Multi-location home-care platform
NLH operates in a structurally relevant home-care market, serving seniors and people needing ongoing support with daily living, mobility, respite, and household tasks. Its multi-location platform provides an established base for expanding service coverage over time.
Negative Factors
Thin and volatile profitability
Although NLH has returned to profitability, its thin net margin leaves limited room for operating setbacks or cost increases. The record of alternating profitable and loss-making years also reduces confidence that current earnings can be sustained consistently.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-location home-care platform
NLH operates in a structurally relevant home-care market, serving seniors and people needing ongoing support with daily living, mobility, respite, and household tasks. Its multi-location platform provides an established base for expanding service coverage over time.
Read all positive factors

Nova Leap Health (NLH) vs. iShares MSCI Canada ETF (EWC)

Nova Leap Health Business Overview & Revenue Model

Company Description
Nova Leap Health Corp. delivers a comprehensive array of in-home and healthcare-at-home solutions across the United States and Canada. Their offerings encompass specialized dementia support, social companionship, assistance with personal needs, an...

Nova Leap Health Financial Statement Overview

Summary
Income statement quality is improving with a return to profitability and modest revenue growth, supported by steady gross margin and positive operating results. However, net margins remain thin and multi-year earnings have been volatile, while cash flow conversion/coverage has been inconsistent despite positive operating and free cash flow. The balance sheet is a key strength with conservative leverage, partially offset by only moderate ROE.
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
56
Neutral
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue33.23M32.02M25.76M26.18M28.21M21.28M
Gross Profit12.94M11.85M9.89M9.77M9.98M7.21M
EBITDA2.71M1.97M2.50M1.35M420.35K4.76M
Net Income1.32M-193.19K1.38M-1.05M-835.75K1.76M
Balance Sheet
Total Assets25.75M23.44M22.39M20.90M23.95M26.77M
Cash, Cash Equivalents and Short-Term Investments1.44M1.49M1.40M894.76K1.27M1.73M
Total Debt4.45M2.93M2.53M1.40M3.97M6.20M
Total Liabilities6.37M4.43M4.14M2.70M5.27M8.29M
Stockholders Equity19.39M19.01M18.25M18.20M18.68M18.48M
Cash Flow
Free Cash Flow1.95M1.42M1.36M2.13M949.49K2.18M
Operating Cash Flow1.91M1.42M1.39M2.15M1.02M2.18M
Investing Cash Flow-2.25M-1.26M-1.59M-23.13K-56.24K-7.40M
Financing Cash Flow388.04K-86.91K729.78K-2.52M-1.41M4.33M

Nova Leap Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.56
Price Trends
50DMA
0.51
Negative
100DMA
0.46
Positive
200DMA
0.40
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
55.75
Neutral
STOCH
82.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Positive. The current price of 0.56 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.51, and above the 200-day MA of 0.40, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.75 is Neutral, neither overbought nor oversold. The STOCH value of 82.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NLH.

Nova Leap Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
C$213.86M7.8625.79%2.43%2.96%―
68
Neutral
C$43.66M23.546.95%―18.35%1021.05%
63
Neutral
C$2.53B20.1336.33%1.96%31.14%34.48%
62
Neutral
C$237.42M8.2045.36%2.45%2.64%-56.04%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
54
Neutral
C$2.18B37.836.58%4.76%16.11%31.75%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:NLH
Nova Leap Health
0.50
0.22
78.57%
TSE:CRRX
CareRx
3.37
-0.05
-1.40%
TSE:EXE
Extendicare
26.57
10.57
66.03%
TSE:SIA
Sienna Senior Living
19.67
1.39
7.57%
TSE:DR
Medical Facilities
14.68
0.56
3.95%

Nova Leap Health Corporate Events

Business Operations and StrategyFinancial Disclosures
Nova Leap to Spotlight Record Quarter and Growth Strategy at Planet MicroCap Showcase
Positive
Oct 14, 2026
Nova Leap Health Corp. will showcase its record second-quarter performance and growth strategy at the Planet MicroCap Showcase in Toronto later this month. President and CEO Chris Dobbin is scheduled to deliver a webcast presentation on October 28...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Nova Leap Health Delivers Record Q2 Results and Accelerates Home Care Expansion
Positive
Aug 7, 2026
Nova Leap Health Corp. reported record financial results for the second quarter of 2026, with revenue rising 17.1% year over year to $9.39 million and trailing twelve-month revenue reaching $33.6 million, the highest in the company’s history...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 17, 2026